Johnson & Johnson (NYSE: JNJ) has reported new long-term Phase 3 results showing sustained skin clearance and symptom improvements with ICOTYDE (icotrokinra), its approved once-daily oral interleukin-23 receptor antagonist for moderate-to-severe plaque psoriasis. Data from the ICONIC-LEAD study, presented at Fall Clinical Dermatology 2026 and announced on October 9, showed that at least 72% of ICOTYDE-treated patients achieved a 90% improvement in psoriasis severity during extended follow-up through Week 112, while at least 70% achieved clear or almost clear skin.
The findings provide additional evidence about the durability of response to an oral targeted therapy in a chronic inflammatory disease that frequently requires long-term treatment. Johnson & Johnson also reported complete skin clearance in more than 44% of treated patients and sustained clinically meaningful improvement in itching among 78%, with no new safety signals identified during the reported follow-up.
The results arrive approximately seven months after the United States Food and Drug Administration approved ICOTYDE in March 2026 for adults and adolescents aged 12 years and older, weighing at least 40 kilograms, who have moderate-to-severe plaque psoriasis and are candidates for systemic therapy or phototherapy. The medicine is also approved in Europe, Japan and China, according to Johnson & Johnson, making its longer-term clinical profile increasingly relevant to dermatologists evaluating treatment options across multiple markets.
The central significance of the new findings is durability rather than initial efficacy. ICOTYDE had already demonstrated statistically significant improvements in psoriasis severity during its pivotal controlled trials, while the latest analysis examines whether patients can maintain substantial clearance over approximately two years. However, the extended results should not be interpreted as a two-year placebo-controlled comparison, and their clinical meaning depends partly on the patients included in the long-term analyses and how missing data were handled.
What do the ICONIC-LEAD Phase 3 results show about ICOTYDE efficacy after two years?
The ICONIC-LEAD trial initially enrolled 684 participants aged 12 years and older with moderate-to-severe plaque psoriasis, including 66 adolescents. Participants were randomised to receive ICOTYDE or placebo, with 456 assigned to the active-treatment group and 228 to placebo. The study evaluated rigorous efficacy outcomes, including at least 90% improvement in the Psoriasis Area and Severity Index, known as PASI 90, and an Investigator’s Global Assessment score of clear or almost clear skin accompanied by a meaningful improvement from baseline.
The newly reported extended results showed that PASI 90 response rates remained at or above 72% from Week 64 through Week 112. During the same period, at least 70% of ICOTYDE-treated patients achieved Investigator’s Global Assessment scores of 0 or 1, corresponding to clear or almost clear skin. These findings suggest that a substantial proportion of patients receiving continued treatment maintained meaningful disease control well beyond the initial efficacy assessment.
Complete clearance outcomes were also sustained. Johnson & Johnson reported that at least 44% of patients achieved PASI 100, indicating complete improvement from baseline on the psoriasis severity index, while at least 46% achieved an Investigator’s Global Assessment score of 0. These are distinct measures of clearance and should not be treated as interchangeable percentages, even though both address the elimination of visible psoriasis activity.
The reported figures are encouraging, but the October disclosure does not provide a complete accounting of patient retention, discontinuations or the exact statistical handling of missing Week 112 outcomes. Those details are important because response rates calculated among patients remaining on treatment can differ from results based on the entire originally randomised population. The percentages therefore describe the company’s reported extended-treatment findings rather than establishing that an identical proportion of every patient initially assigned to ICOTYDE maintained response for 112 weeks.
How do the two-year findings compare with ICOTYDE’s original placebo-controlled results?
The original ICONIC-LEAD efficacy analysis provides a useful reference point for understanding the longer-term findings. According to the FDA’s regulatory review, approximately 49.6% of ICOTYDE recipients achieved PASI 90 at Week 16, compared with 4.4% receiving placebo. Clear or almost clear skin was reported in approximately 64.7% of the active-treatment group, versus 8.3% in the placebo group.
Those earlier results established a statistically significant treatment effect under randomised, controlled conditions and contributed to the evidence supporting regulatory approval. The subsequent increase in reported PASI 90 response rates during extended follow-up suggests that clinical improvement may continue beyond the first four months for some patients. However, comparing Week 16 and Week 112 response rates requires consideration of changes in the analysis population and trial design.
The long-term assessment is particularly relevant because psoriasis severity can fluctuate, and some systemic treatments lose effectiveness or become difficult to continue over prolonged periods. Maintaining substantial skin clearance may reduce the need for additional therapies or treatment changes, although the latest disclosure does not quantify reductions in rescue medication, healthcare utilisation or treatment switching. These outcomes would require additional evidence.
ICOTYDE’s results also illustrate why durability is an important consideration in chronic inflammatory disease. Rapid initial improvement may influence early treatment decisions, but sustained disease control determines whether a medicine remains useful over years of management. The Week 112 observations add information about that longer treatment horizon without replacing the stronger causal evidence provided by the original randomised comparisons.
Why does sustained itch improvement matter alongside psoriasis skin clearance?
Johnson & Johnson reported that 78% of ICOTYDE-treated patients maintained clinically meaningful improvement in itching from Week 64 through Week 112. Itching is a major component of psoriasis disease burden and can contribute to disturbed sleep, impaired concentration, discomfort and reduced quality of life. Improvements in visible plaques do not necessarily capture every aspect of patients’ experiences, making symptom-focused assessments an important complement to physician-rated disease severity.
The sustained itch findings suggest that benefits may extend beyond improvements measured through PASI and Investigator’s Global Assessment scores. For people with persistent symptoms, reducing itching can be clinically meaningful even when some visible skin disease remains. However, the October announcement does not provide the complete itch assessment scale, baseline distribution or detailed statistical analysis needed to independently evaluate the magnitude of the reported long-term response.
The inclusion of both skin clearance and patient-reported symptom measures strengthens the clinical relevance of the dataset. Dermatologists evaluating systemic therapy must consider not only lesion reduction but also the extent to which treatment addresses symptoms affecting daily activities. Future real-world studies could provide additional insight into whether sustained symptom control is associated with improvements in sleep, treatment satisfaction and continued therapy use.
What does the 85% response recovery rate reveal about stopping and restarting ICOTYDE?
Another clinically relevant finding concerns patients who responded to ICOTYDE before treatment withdrawal. Johnson & Johnson reported that 85% of patients who had achieved PASI 90 and were withdrawn from treatment at Week 24 regained PASI 90 within 24 weeks after restarting therapy. The result provides information about the potential to recapture treatment response following an interruption.
Treatment interruption can arise in routine practice for several reasons, including infections, access difficulties, tolerability concerns and changes in patient circumstances. A medicine that can restore efficacy after an interruption may offer practical flexibility, although the degree of response recovery can vary according to the duration of interruption and individual disease characteristics. The ICONIC-LEAD finding offers evidence from a defined group of previous responders rather than establishing recovery rates for every patient who stops treatment.
The reported percentage also should not be confused with evidence that ICOTYDE maintains disease control after discontinuation. Regaining PASI 90 after restarting treatment is different from remaining in remission without medication, and the announcement does not establish that long-term treatment is unnecessary. More detailed withdrawal analyses would help clarify the timing of disease recurrence and response restoration.
How does ICOTYDE’s oral IL-23 receptor blockade differ from injectable psoriasis biologics?
ICOTYDE is a targeted oral peptide that inhibits signalling through the interleukin-23 receptor, a component of the inflammatory pathway involved in plaque psoriasis. The medicine was jointly discovered through a collaboration between Johnson & Johnson and Protagonist Therapeutics Incorporated, which retains an economic interest in its commercial performance. Unlike conventional small-molecule oral immunomodulators, icotrokinra uses peptide technology to target the IL-23 receptor directly.
The mechanism is relevant because the IL-23 pathway has already been validated as a therapeutic target through injectable biologic medicines, including Johnson & Johnson’s TREMFYA (guselkumab). Those treatments bind IL-23 itself, whereas ICOTYDE inhibits the receptor involved in transmitting its biological signal. Both approaches influence an established inflammatory pathway, but they differ in molecular design, administration and pharmacological characteristics.
ICOTYDE offers oral administration, with the approved United States dose consisting of one 200 mg tablet daily. The prescribing information specifies administration upon waking with water on an empty stomach, followed by a wait of at least 30 minutes before eating. This creates a different treatment routine from injectable biologics, many of which are administered at intervals measured in weeks or months.
An oral formulation may appeal to patients who prefer avoiding injections, but daily dosing introduces its own adherence requirements. The clinical value of convenience will depend on whether patients can follow the administration schedule consistently and maintain adequate disease control. The current two-year data do not establish that ICOTYDE is superior to injectable IL-23 inhibitors, since ICONIC-LEAD was not designed as a direct comparison against those treatments.
Can ICOTYDE compete with SOTYKTU and other oral therapies for moderate-to-severe psoriasis?
The oral systemic treatment landscape includes SOTYKTU (deucravacitinib), the selective TYK2 inhibitor marketed by Bristol Myers Squibb. Johnson & Johnson evaluated ICOTYDE against deucravacitinib in the separate Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 studies, providing direct comparative evidence rather than relying exclusively on cross-trial observations.
In ICONIC-ADVANCE 1, PASI 90 responses at Week 16 were achieved by approximately 55% of ICOTYDE recipients compared with 30% receiving deucravacitinib. The corresponding figures in ICONIC-ADVANCE 2 were approximately 58% and 35%, respectively, with statistically significant differences favouring ICOTYDE. These findings support superior efficacy on the specified endpoint during the controlled assessment period, but they do not establish superiority across all safety, adherence or long-term clinical outcomes.
The additional two-year ICONIC-LEAD findings strengthen evidence of continued disease control with ICOTYDE but should not be used to extend the head-to-head superiority conclusion to Week 112. Treatment persistence, tolerability and patient preferences may differ substantially in routine clinical settings. Commercial competition will also depend on reimbursement arrangements and the availability of established oral and injectable alternatives.
The results give Johnson & Johnson a differentiated position across both oral and injectable IL-23-targeted treatment approaches. Its broader psoriasis portfolio includes established biologic therapies, while ICOTYDE offers an alternative administration format within a well-characterised inflammatory pathway. How physicians select between these options will depend on the individual patient’s disease severity, treatment history, clinical circumstances and access to therapy.
What does the Week 112 safety update establish about long-term ICOTYDE treatment?
Johnson & Johnson reported that the safety findings through Week 112 remained consistent with ICOTYDE’s established clinical profile, with no new safety signals identified. This is relevant for a therapy intended for chronic administration, particularly because immunomodulatory treatments require consideration of infection risks and other potential adverse reactions. However, the absence of a newly identified signal does not demonstrate that prolonged treatment is free from risk.
The United States prescribing information includes warnings concerning infections, tuberculosis and immunisation. The medicine should not be used during clinically important active infections until they have resolved or been adequately treated, and the label advises avoidance of live vaccines during treatment. The prescribing information also addresses monitoring considerations in patients with moderate or severe renal impairment.
Across the original pooled placebo-controlled Phase 3 safety studies through Week 16, the most commonly identified adverse reactions included headache, nausea, cough, fungal infections and fatigue. Serious infections occurred in 0.2% of ICOTYDE-treated participants compared with 0.4% receiving placebo during that controlled period. Those short-term percentages should not be treated as definitive estimates of long-term infection risk or compared directly with unrelated clinical trials.
The newly presented Week 112 findings extend clinical exposure, but the announcement does not provide a detailed updated breakdown of serious adverse events, treatment discontinuations or exposure-adjusted event rates. These data would help clinicians evaluate whether adverse events accumulate or change over time. Broader post-marketing surveillance will also be important as the medicine reaches patient populations less selectively enrolled than those participating in controlled clinical trials.
How could the two-year results support Johnson & Johnson’s global ICOTYDE commercial strategy?
The timing of the results is commercially relevant because ICOTYDE entered the United States market in 2026 and has received authorisations in other major pharmaceutical markets. Long-term efficacy information can support physician confidence in a treatment intended for sustained disease management, particularly when patients and payers have access to several established systemic alternatives.
For Johnson & Johnson, ICOTYDE adds another commercial opportunity within immunology as the company manages competition affecting older products. Its second-quarter 2026 financial results showed worldwide sales of approximately $25.3 billion, with growth supported partly by newer medicines including TREMFYA. The company continues to invest in innovative treatments as established franchises face changing competitive and exclusivity conditions.
The collaboration with Protagonist Therapeutics provides another financial dimension. Protagonist received a $50 million milestone following the United States approval and is entitled to tiered royalties of 6% to 10% on worldwide ICOTYDE net sales, along with potential additional regulatory and commercial milestone payments. These arrangements link the biotechnology company’s future revenue to Johnson & Johnson’s ability to expand the medicine’s commercial reach.
Nevertheless, the October long-term efficacy announcement does not establish ICOTYDE’s eventual peak sales, market share or profitability. Commercial performance will depend on physician adoption, patient access, reimbursement coverage, international launch execution and treatment persistence. The presence of durable clinical responses strengthens the product’s competitive evidence, but revenue expectations still require observed commercial performance.
Johnson & Johnson shares closed at $261.44 on October 9, 2026, an increase of 1.93% from the previous session. The movement coincided with the new clinical disclosure and a broader rise in United States equity markets, making it inappropriate to attribute the gain specifically to ICOTYDE. Investor expectations for Johnson & Johnson also reflect its much larger pharmaceutical and medical technology portfolio.
What do the additional ICONIC trials suggest about the future development of icotrokinra?
The ICONIC programme extends beyond the original ICONIC-LEAD study. Earlier in October, Johnson & Johnson reported two-year findings from ICONIC-TOTAL, which examined psoriasis affecting high-impact anatomical areas, including the scalp, genitals, hands and feet. At Week 112, the company reported complete clearance in 60% of patients with scalp psoriasis and 89% of those with genital psoriasis within the relevant assessed populations.
These findings complement the broader skin clearance data because disease affecting sensitive or highly visible areas can create substantial symptoms and functional limitations even when the overall affected body surface area is relatively limited. Nevertheless, ICONIC-TOTAL and ICONIC-LEAD enrolled patients according to different eligibility criteria and evaluated distinct clinical outcomes. Their percentages should not be used to infer that treatment is more effective in one anatomical region than another.
Johnson & Johnson is also investigating icotrokinra in other inflammatory conditions, including active psoriatic arthritis, ulcerative colitis and Crohn’s disease. These programmes reflect the broader potential of targeting IL-23 receptor signalling, but the additional indications remain investigational and require their own clinical and regulatory evidence. Approval for plaque psoriasis does not establish efficacy or marketing authorisation for these other diseases.
What will determine ICOTYDE’s clinical position after the two-year Phase 3 results?
The Week 112 findings strengthen evidence that substantial skin clearance can be maintained during extended ICOTYDE treatment, adding useful information for dermatologists considering long-term systemic therapy. The combination of PASI 90 responses, complete clearance, itch improvement and response recovery after retreatment provides several dimensions of clinical performance beyond the original regulatory efficacy endpoints.
The remaining questions concern how these findings translate into routine care, including treatment persistence, real-world safety and comparative effectiveness against established alternatives. Complete reporting of long-term patient disposition and missing-data analyses would also help clarify the durability estimates. These considerations are particularly relevant as use expands beyond the controlled clinical trial population.
For Johnson & Johnson, ICOTYDE’s commercial opportunity rests on combining an established inflammatory target with an oral delivery format that may suit patients seeking alternatives to injections. The two-year data provide evidence supporting that proposition, but they do not guarantee that daily oral therapy will replace established biologic treatment strategies.
The next meaningful assessment will come from sustained clinical use and real-world evidence showing whether patients can maintain the improvements observed in the ICONIC trials while managing the medicine’s administration and safety requirements. ICOTYDE has already demonstrated regulatory efficacy and extended clinical responses; its longer-term position in psoriasis care will depend on how reliably those results translate into routine treatment.
